Want to see TSE:NARA full AI Analyst Report?
NARA Stock Chart & Stats
C$0.33
C$0.01(3.13%)
At close: 4:00 PM EDT
C$0.33
C$0.01(3.13%)
Day’s Range― - ―
52-Week RangeC$0.20 - C$2.24
Previous CloseN/A
Volume6.08K
Average Volume (3M)8.99K
Market Cap
C$3.51M
Enterprise ValueC$10.18
Total Cash (Recent Filing)C$7.72K
Total Debt (Recent Filing)C$715.34K
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding14,046,870
10 Day Avg. Volume0
30 Day Avg. Volume8,992
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-3.87
Price to Sales (P/S)0.00
P/FCF Ratio-4.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Reported EPS GrowthReported EPS growth provides a measurable improvement in per-share results despite the company remaining loss-making. If sustained, this could support better earnings quality over the next several quarters, although the current pre-revenue position means it has not yet translated into profitability.
Free Cash Flow ImprovementFree cash flow improved compared with 2025, indicating some movement in the right direction in cash performance. This is a constructive operational signal over the medium term, though the company still burns substantial cash and remains dependent on further improvement to become self-funding.
Operating-investment Loss ProfileThe stated loss profile is attributed to operating investment rather than volatile revenue swings, which may make results more predictable as the business develops. That could support future operating leverage, provided investment eventually produces revenue and the company controls its cash use.
Bears Say
Pre-revenue And Widening LossesThe company has not yet established revenue generation, while losses have widened across recent periods. This signals that the core business is still pre-commercial or not producing reported sales, leaving execution risk high and making durable profitability dependent on future operating progress.
Persistent Cash BurnPersistent negative operating and free cash flow shows that the business is not currently self-funding its operations. Continued cash burn can reduce financial flexibility over the next several quarters and increase the importance of obtaining external capital or materially improving operating performance.
Negative Equity And Limited Balance-sheet CushionNegative shareholders’ equity and a very small asset base indicate accumulated deficits and little balance-sheet protection against further losses. This weakens financial flexibility, leaves limited capacity to absorb setbacks, and increases reliance on external financing to sustain operations.
PanGenomic Health, Inc. Class A News
NARA FAQ
What was PanGenomic Health, Inc. Class A’s price range in the past 12 months?
PanGenomic Health, Inc. Class A lowest stock price was C$0.20 and its highest was C$2.24 in the past 12 months.
What is PanGenomic Health, Inc. Class A’s market cap?
PanGenomic Health, Inc. Class A’s market cap is C$3.51M.
When is PanGenomic Health, Inc. Class A’s upcoming earnings report date?
PanGenomic Health, Inc. Class A’s upcoming earnings report date is Nov 26, 2026 which is in 56 days.
How were PanGenomic Health, Inc. Class A’s earnings last quarter?
PanGenomic Health, Inc. Class A released its earnings results on Aug 31, 2026. The company reported -C$0.027 earnings per share for the quarter.
Is PanGenomic Health, Inc. Class A overvalued?
According to Wall Street analysts PanGenomic Health, Inc. Class A’s price is currently Overvalued.
Does PanGenomic Health, Inc. Class A pay dividends?
PanGenomic Health, Inc. Class A does not currently pay dividends.
What is PanGenomic Health, Inc. Class A’s EPS estimate?
PanGenomic Health, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PanGenomic Health, Inc. Class A have?
PanGenomic Health, Inc. Class A has 14,046,870 shares outstanding.
What happened to PanGenomic Health, Inc. Class A’s price movement after its last earnings report?
PanGenomic Health, Inc. Class A reported an EPS of -C$0.027 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PanGenomic Health, Inc. Class A?
Currently, no hedge funds are holding shares in TSE:NARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PanGenomic Health, Inc. Class A
Pangenomic Health Inc. is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The company's mobile app, the Nara App, provides consumers with a knowledge base tailored to an individual's unique user profile. Its PlantGx Platform provides health practitioners with access to a consumer's Nara App data to assist them in optimizing the identification of appropriate natural remedies and monitoring a patient's prognosis.
Technical Analysis
Diagnos
―
nDatalyze Corp
―
Rocket Doctor AI
―
UniDoc Health Corp
―
DiagnaMed Holdings Corp.
―